SG Americas Securities LLC Buys 748,525 Shares of Taysha Gene Therapies, Inc. $TSHA

SG Americas Securities LLC lifted its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 2,271.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 781,474 shares of the company’s stock after purchasing an additional 748,525 shares during the quarter. SG Americas Securities LLC’s holdings in Taysha Gene Therapies were worth $4,298,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in TSHA. B Group Inc. lifted its holdings in Taysha Gene Therapies by 43.4% during the 2nd quarter. B Group Inc. now owns 1,800,556 shares of the company’s stock valued at $4,159,000 after purchasing an additional 545,000 shares during the last quarter. Rice Hall James & Associates LLC bought a new stake in Taysha Gene Therapies during the third quarter worth about $1,890,000. Ally Bridge Group NY LLC bought a new stake in Taysha Gene Therapies during the third quarter worth about $6,207,000. GSA Capital Partners LLP increased its holdings in shares of Taysha Gene Therapies by 969.0% during the third quarter. GSA Capital Partners LLP now owns 477,749 shares of the company’s stock worth $1,562,000 after buying an additional 433,059 shares in the last quarter. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Taysha Gene Therapies during the second quarter worth approximately $462,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on TSHA shares. UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. The Goldman Sachs Group set a $11.00 price target on Taysha Gene Therapies in a report on Thursday, December 4th. Wells Fargo & Company lifted their price objective on Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Needham & Company LLC boosted their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Taysha Gene Therapies has a consensus rating of “Buy” and a consensus price target of $11.09.

Taysha Gene Therapies Trading Down 3.6%

TSHA opened at $4.31 on Thursday. The firm has a 50 day simple moving average of $4.56 and a 200 day simple moving average of $4.62. Taysha Gene Therapies, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $6.02. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -12.68 and a beta of 1.02. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. The company had revenue of $5.49 million for the quarter, compared to the consensus estimate of $1.89 million. On average, sell-side analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Insider Activity at Taysha Gene Therapies

In related news, CFO Kamran Alam sold 78,968 shares of the firm’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00. Following the sale, the chief financial officer directly owned 1,467,635 shares in the company, valued at $6,971,266.25. This trade represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Sean P. Nolan sold 136,789 shares of the business’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the sale, the chief executive officer directly owned 2,949,569 shares in the company, valued at $14,010,452.75. This represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 598,623 shares of company stock worth $2,822,188. 3.78% of the stock is owned by company insiders.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.